Full-Time
Portable bedside MRI system for hospitals
$143.5k - $165k/yr
No H1B Sponsorship
Branford, CT, USA
In Person
Hyperfine creates medical imaging tools for hospitals, focusing on the Swoop system, the first FDA-cleared portable ultra-low field MRI that can image a patient’s brain at the bedside. How it works: a compact, portable MRI device is brought to the patient in settings like intensive care units, performing brain scans without moving the patient to a radiology suite. The open, safe design allows family members to stay nearby during imaging. Differentiation: it is already FDA-cleared and designed for point-of-care use, enabling bedside decision-making, faster treatment decisions, quicker discharges, and more efficient use of hospital staff and resources at a lower cost compared to traditional MRI workflows. Revenue model: Hyperfine sells the Swoop system and related services to hospitals, clinics, and other healthcare facilities. Goal: improve patient care by bringing diagnostic imaging directly to patients, increasing access to timely brain imaging and streamlining clinical workflows.
Company Size
51-200
Company Stage
IPO
Headquarters
Guilford, Connecticut
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
People at Hyperfine who can refer or advise you
Remote Work Options
Hybrid Work Options
Wellness Program
Mental Health Support
Hyperfine has received CE marking and UK Conformity Assessment approval for its next-generation Swoop portable MRI system and latest Optive AI software, enabling commercialisation across Europe and the UK. The approvals mark a key milestone in the company's international growth strategy. The next-generation Swoop system, FDA-cleared in Q2 2025, delivers improved image quality and workflow for brain imaging. The updated Optive AI software includes multi-direction diffusion-weighted imaging capabilities, enhancing stroke detection similar to high-field MRI scanners. The technology is currently distributed across over a dozen European countries through Hyperfine's network. The company plans to begin commercialisation of the new system and software in Europe and the UK in early Q3 2026, ahead of internal expectations.
Hyperfine Inc reported record fourth-quarter revenue of $5.3 million, up 128% year-over-year, driven by strong performance of its next-generation Swoop scanner. The medical imaging company sold 16 units in Q4, compared to nine units in the prior-year period. Gross margin expanded to 50.9%, up 1,530 basis points from Q4 2024, whilst net loss narrowed to $5.9 million from $10.4 million. Full-year 2025 revenue reached $13.6 million, up 5% from 2024. The company received FDA clearance for updated Optive AI software and gained approval for its first-generation Swoop system in India. Hyperfine reduced cash burn by 30% year-over-year to $5.7 million. For 2026, the company projects revenue of $20 million to $22 million, representing 55% growth at the midpoint, with gross margins of 50% to 55%.
Hyperfine reported fourth-quarter revenue exceeding $5 million, driven by accelerating adoption of its second-generation Swoop portable brain MRI system and Optive AI software. CEO Maria Sainz described the combination as a "market turning point" for portable brain MRI, highlighting diagnostic-quality imaging from ultra-low field magnets. The company has sold over a dozen next-generation systems since June 2025, focusing on critical care, emergency departments and neurology offices. The FDA cleared a software update in December 2025 featuring diffusion-weighted imaging for stroke workflows. Hyperfine cited external validation including published health economic data from Jefferson Abington Hospital showing cost savings across 143 scans. Yale School of Medicine's PRIME study evaluating AI-powered portable MRI in emergency departments completed enrollment ahead of schedule, with results expected later in 2026.
Hyperfine arranged a $40M senior secured loan with Horizon, drawing $15M initially, at a minimum 10.75% rate and issuing over 1.0M stock warrants at $1.20 per share.
$3.7M grant supports expanded use of portable MRI to evaluate brain development and guide targeted health interventions in underserved communities.